The FDA has approved tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea in adults with obesity. This injectable drug is the first-ever treatment for OSA, and is used in combination with diet and exercise. The drug was initially approved for type 2 diabetes and weight loss. Clinical trials showed significant improvement in OSA symptoms and weight loss in participants. However, side effects include nausea, diarrhea, and injection site reactions. Adherence to tirzepatide therapy is critical, especially considering racial disparities in medical care. The addition of tirzepatide as a treatment option for OSA requires attention to optimizing treatment adherence and addressing disparities in care.
Source link
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
